A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception

The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive Yasmin and Marvelon on cycle control in healthy Chinese...

Date First Received: September 13, 2005

Last Updated: January 13, 2009

Verified by: Bayer, January 2009

Clinical Trial Phase: Phase 3 | Start Date: November 2003

Overall Status: Completed

Estimated Enrollment: 842

Brief Summary

Official Title: “An Open-Label, Randomised, Parallel-Group Comparison to Investigate the Efficacy of Yasmin® (30 µg Ethinylestradiol, 3mg Drospirenone) and Marvelon® (30 µg Ethinylestradiol, 150 µg Desogestrel) on Cycle Control in Healthy Chinese Women Over 13 Cycles”

Condition Keyword(s):

Intervention(s):

The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive Yasmin and Marvelon on cycle control in healthy Chinese women

Study Type: Interventional

Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Study Primary Completion Date: March 2006

Detailed Clinical Trial Description

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.

Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Intervention(s) in this Clinical Trial

  • Drug: Yasmin
    • 30 µg ethinylestradiol, 3mg drospirenone
  • Drug: Marvelon
    • 30 µg ethinylestradiol, 150 µg desogestrel

Arms, Groups and Cohorts in this Clinical Trial

  • Active Comparator: Arm 1
  • Active Comparator: Arm 2

Outcome Measures for this Clinical Trial

Primary Measures

  • The primary efficacy variable is the comparison of cycle control from randomisation to cycle 13. This will be based on the number of subjects reporting at least 1 unexpected intracyclic bleeding episode between cycles 2 to 13.
    • Time Frame: 13 treatment cycles (1 cycle= 28 days)
      Safety Issue?: No

Secondary Measures

  • Weight changes
    • Time Frame: 13 treatment cycles
      Safety Issue?: No
  • Contraceptive reliability
    • Time Frame: 13 treatment cycles
      Safety Issue?: No
  • Effects on skin condition
    • Time Frame: 13 treatment cycles
      Safety Issue?: No
  • Changes in MDQ subscale scores
    • Time Frame: 13 treatment cycles
      Safety Issue?: No
  • Adverse Events
    • Time Frame: the whole study period
      Safety Issue?: Yes

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Healthy Chinese female requesting contraceptives

Exclusion Criteria:

  • Vascular, metabolic, hepatic, renal, oncologic and other diseases

Gender Eligibility for this Clinical Trial: Female

Minimum Age for this Clinical Trial: 20 Years

Maximum Age for this Clinical Trial: 35 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers

Clinical Trial Sponsor Information

Lead Sponsor: Bayer

Overall Clinical Trial Officials and Contacts

Bayer Study Director Study Director Bayer  

Additional Information

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00185419

Study ID Number: 91330

ClinicalTrials.gov Identifier: NCT00185419

Health Authority: China: State Food and Drug Administration

Click here and search for drug information provided by the FDA

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product

Click here to find results for studies related to marketed products

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.